M. Asano

发表

COMPARATIVE STUDY ON α1‐ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA

S. Yamada, T. Takenaka, K. Honda, 1994 .

Pharmacokinetics and Cardiovascular Effects of YM‐21095, a Novel Renin Inhibitor, in Dogs and Monkeys

T. Takenaka, M. Shibasaki, T. Usui, 1994, The Journal of pharmacy and pharmacology.

Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes.

M. Michel, S. Sato, M. Asano, 1997, The Journal of pharmacology and experimental therapeutics.

Effect of YM934, a KATP channel opener, on airway hyperresponsiveness induced by platelet activating factor in guinea-pigs

J. Ishikawa, M. Asano, C. Saitoh, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

Effect of YM294, recombinant human interleukin-11, on carboplatin-induced thrombocytopenia in rats.

M. Asano, K. Taguchi, 1995, Journal of pharmaceutical sciences.

Antihypertensive and adrenoceptor blocking properties of new sulfonamide-substituted phenylethylamines.

T. Takenaka, K. Honda, K. Shiono, 1982, Clinical and experimental hypertension. Part A, Theory and practice.

Hemodynamic characterization of YM435, a novel dopamine DA1 receptor agonist, in anesthetized dogs.

T. Takenaka, A. Tanaka, K. Honda, 1997, Journal of cardiovascular pharmacology.

Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs.

Y. Arai, T. Takenaka, K. Honda, 1997, European journal of pharmacology.

Antianginal effects of YM430, a novel calcium entry-blocking and beta-adrenoceptor-blocking agent in several experimental angina models.

Y. Arai, T. Takenaka, W. Uchida, 1997, General pharmacology.

Novel potassium channel activators: synthesis and structure-activity relationship studies of 3,4-dihydro-2H-1,4-benzoxazine derivatives.

Y. Matsumoto, W. Uchida, M. Asano, 1996, Chemical & pharmaceutical bulletin.

Pharmacological properties of YM-15430-1, a 1,4-dihydropyridine derivative with beta 1-adrenoceptor-blocking activity.

T. Takenaka, W. Uchida, O. Inagaki, 1994, Archives internationales de pharmacodynamie et de therapie.

Antianginal Effects of YM‐16151–4 in Various Experimental Angina Models

T. Takenaka, W. Uchida, M. Asano, 1993, Journal of cardiovascular pharmacology.

Pharmacological profiles of YM-16151-1 and its optical isomers: a novel calcium entry blocking and selective beta-1 adrenoceptor blocking agent.

M. Terai, T. Takenaka, Y. Matsumoto, 1990, The Journal of pharmacology and experimental therapeutics.

Effect of YM934, a Novel Potassium‐Channel Opener, in Various Experimental Asthma Models in Guinea‐pigs

J. Ishikawa, K. Masaki, M. Asano, 1996, The Journal of pharmacy and pharmacology.

Vasodilator and hypotensive effects of the optical isomers of nicardipine (YC-93), a new Ca2+-antagonist.

M. Asano, S. Higuchi, H. Maeno, 1982, Japanese journal of pharmacology.

Pharmacological profile of nicardipine hydrochloride in anesthetized dogs with acute heart failure. Part 1: Hemodynamic effects in normal dogs and dogs with acute heart failure.

K. Momose, S. Usuda, J. Maehara, 1998, Arzneimittel-Forschung.

EFFECT OF BARNIDIPINE ON BLOOD FLOW TO MAJOR ORGANS AND RENAL FUNCTION IN ANAESTHETIZED DOGS AND SPONTANEOUSLY HYPERTENSIVE RATS

K. Masaki, M. Asano, J. Ishikawa, 1995, Clinical and experimental pharmacology & physiology. Supplement.

Adrenoceptor blocking, hemodynamic and coronary effects of YM-09538, a new combined α- and β-adrenoceptor blocking drug, in anesthetized dogs

T. Takenaka, J. Giudicelli, A. Berdeaux, 1982 .

Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives.

T. Furuya, K. Honda, M. Yokota, 1991, Chemical & pharmaceutical bulletin.

Cardiovascular pharmacology of nicardipine in animals.

T. Takenaka, K. Shiono, M. Shibasaki, 1985, British journal of clinical pharmacology.

Effect of tamsulosin, a novel alpha 1-adrenoceptor antagonist, on urethral pressure profile in anaesthetized dogs.

K. Sudoh, T. Takenaka, H. Tanaka, 1996, Journal of autonomic pharmacology.

Cardiovascular properties of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N- methylbenzamide.

K. Takasuna, M. Hirohashi, K. Tamura, 1993, Arzneimittel-Forschung.

[Discovery and development of tamsulosin hydrochloride, a new alpha 1-adrenoceptor antagonist].

T. Takenaka, K. Honda, M. Asano, 1995, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Comparative study on alpha 1-adrenoceptor antagonist binding in human prostate and aorta.

S. Yamada, T. Takenaka, K. Honda, 1994, Clinical and experimental pharmacology & physiology.

Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats.

T. Takenaka, N. Masuda, W. Uchida, 1997, Biological & pharmaceutical bulletin.

In vitro and in vivo vasodilatory activity of barnidipine and its enantiomers.

T. Takenaka, O. Inagaki, M. Asano, 1999, Biological and Pharmaceutical Bulletin.

Cardiovascular Effects of YM‐16151–4: A Novel Calcium Entry Blocking and Selective β1-Adrenoceptor Blocking Agent in Rats and Dogs

T. Takenaka, W. Uchida, Yasuko Matsuda, 1993, Journal of Cardiovascular Pharmacology.

Amosulalol, a combined alpha and beta adrenoceptor antagonist: Kinetics after intravenous and oral doses

M. Nakashima, T. Seki, T. Takenaka, 1984, Clinical pharmacology and therapeutics.